CoChat

Characterization of the Safety and Pharmacokinetic Profile of d-Methadone, a Novel N-Methyl-d-Aspartate Receptor Antagonist in Healthy, Opioid-Naive Subjects: Results of Two Phase 1 Studies

Bernstein, Galina, Davis, Kelly, Mills, Catherine, Wang, Lu, McDonnell, Michael, Oldenhof, John, Inturrisi, Charles, Manfredi, Paolo L., Vitolo, Ottavio V. · 2019 · Journal of Clinical Psychopharmacology
Cited by 37

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Purpose/Background: N-methyl-d-aspartate (NMDA) receptor (NMDAR) antagonists are potential agents for the treatment of several central nervous system disorders including major depressive disorder. Racemic methadone,l-methadone, and d-methadone all bind the NMDAR with an affinity similar to that of established NMDAR antagonists, whereas only l-methadone and racemic methadone bind to opioid receptors with high affinity. Therefore,d-methadone is expected to have no clinically significant opioid effects at therapeutic doses mediated by its NMDAR antagonism. Methods: We conducted 2 phase 1, double-blind, randomized, placebo-controlled, single- and multiple-ascending-dose studies to investigate the safety and tolerability of oral d-methadone and to characterize its pharmacokinetic profile in healthy opioid-naive volunteers. Results: d-Methadone exhibits linear pharmacokinetics with dose proportionality for most single-dose and multiple-dose parameters. Single doses up to 150 mg and daily doses up to 75 mg for 10 days were well tolerated with mostly mild treatment-emergent adverse events and no severe or serious adverse events. Dose-related somnolence and nausea occurred and were mostly present at the higher dose level. There was no evidence of respiratory depression, dissociative and psychotomimetic effects, or withdrawal signs and symptoms upon abrupt discontinuation. An overall dose-response effect was observed, with higher doses resulting in larger QTcF (QT interval corrected using Fridericia formula) changes from baseline, but none of the changes were considered clinically significant by the investigators. Mild, dose-dependent pupillary constriction of brief duration occurred particularly at the 60-mg dose or above in the single-ascending-dose study and at the dose of 75 mg in the multiple-ascending-dose study. No detectable conversion of d-methadone to l-methadone occurred in vivo. Conclusions: These results support the safety and continued clinical development of d-methadone as an NMDAR antagonist for the treatment of depression and other central nervous system disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jcp.0000000000001035

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 37

Metadata

Authors
Bernstein, G., Davis, K., Mills, C., Wang, L., McDonnell, M., Oldenhof, J., Inturrisi, C., Manfredi, P. L., & Vitolo, O. V.
Venue
Journal of Clinical Psychopharmacology
Published
2019-05
Volume
39
Issue
3
Pages
226-237
ISSN
  • 0271-0749 (ISSN-L)
  • 1533-712X
OpenAlex
W2925451033
Cited by
37
References
4
FWCI
2.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of the Safety and Pharmacokinetic Profile of d-Methadone, a Novel N-Methyl-d-Aspartate Receptor Antagonist in Healthy, Opioid-Naive Subjects: Results of Two Phase 1 Studies. https://app.cochat.ai/papers/10.1097/jcp.0000000000001035
The paper
Bernstein, G., Davis, K., Mills, C., Wang, L., McDonnell, M., Oldenhof, J., Inturrisi, C., Manfredi, P. L., & Vitolo, O. V. (2019). Characterization of the Safety and Pharmacokinetic Profile of d-Methadone, a Novel N-Methyl-d-Aspartate Receptor Antagonist in Healthy, Opioid-Naive Subjects: Results of Two Phase 1 Studies. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000001035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.